We are a privately held biotechnology company that has developed a diagnostic platform allowing for disease management and diagnosis through prognosis, all from a simple blood test. The Biofluidica diagnostic platform is able to precisely capture and isolate disease biomarkers, such as Circulating Tumor Cells, CTC's, and has been clinically validated. Our ability to scan blood for the first signs of a disease, finding the rarest biomarkers with unmatched sensitivity, means fulfilling the promise of a true liquid biopsy. We are revolutionizing disease diagnostics by bringing better diagnostics to millions of people.

Liquid Biopsy

Biomarkers identified in tissue are ideally suited as disease indicators and can be used in diagnostics. However, tissue, in some cases, can be extremely difficult to acquire from the patient and may not be representative of the heterogeneity of the disease of interest. Liquid biopsies can supply a vast array of different types of biomarkers, thereby circumventing the need for tissue. One type of biomarker is a Circulating Tumor Cell, CTC. In a sample with six million white blood cells and five billion red blood cells, only one viable CTC may be present. BioFluidica's diagnostic test can find this one CTC with unmatched accuracy.